Dynamk Capital is a growth equity and venture fund entirely focused on Life Science Industrials: the services, tools, technologies that are critical for discovery, development and manufacturing in biopharma. Dynamk is focused on companies that are developing innovative and disruptive technologies that enable the full biopharma continuum across discovery, development, and manufacturing of therapeutics, biologics, vaccines and cell & gene therapies. The Dynamk Capital team works to develop collaborative partnerships while leveraging their knowledge and expertise to advance their portfolio of companies.
Dynamk Capital works closely with entrepreneurs and innovators to identify growth strategies, accelerate growth and commercialization, and develop exit pathways. Dynamk’s portfolio companies are enabling the future of biologics, cell and gene therapies, vaccines and regenerative medicine. These companies include; CellFE Biotech, Curi Bio, Envisagenics, Lightspeed, Lucid Scientific, RoosterBio, and Vectron Biosolutions. Dynamk Capital has also previously invested in FloDesign Sonics (acquired by MilliporeSigma).